Table 4.
Budget impact analyses
| Parameter | Modeled for 100 CDI patients | Differencea | |
|---|---|---|---|
| Pre-implementation | Treatment pathway | ||
| Clinical impact at 90-day follow-up | |||
| CDI recurrence (n, patients) | 27 | 15 | − 12 |
| Sustained response (n, patients) | 56 | 73 | 17 |
| CDI-related readmissions (n, patients) | 19 | 9 | − 10 |
| Readmission length of stay (n, bed-days)b | 95 | 45 | − 50 |
| Economic impact at 90-day follow-up | |||
| Index admission direct costs, overall, $ | $836,233 | $707,660 | − $128,573 |
| CDI-related readmission direct costs, overall, $ | $135,236 | $40,914 | − $94,322 |
| Total direct costs (index + readmission), $ | $971,469 | $748,574 | − $222,895 |
| Overall impact | |||
| Overall Direct Cost Savings,a $ | $222,895 | ||
| Savings per additional patient with sustained response,c $ | $5548 | ||
| Savings per CDI-related readmission avoided,d $ | $9432 | ||
| Savings per bed-day avoided,e $ | $1886 | ||
aPost-implementation of treatment pathway minus pre-implementation
bMedian of 5 days used for both due to non-significant difference [6 (4–10) vs. 4.5 (2–4.5), p = 0.251]
cEquals savings from CDI-related readmission costs/the additional number of patients with sustained response
dEquals savings from CDI-related readmission costs/the number of CDI-related readmissions avoided
eEquals savings from CDI-related readmission costs/the number of bed-days saved